Chicago Tribune Food Awards winners map
Since 2011, some form of the Chicago Tribune Food Awards have been held, honoring the best of the Chicago food scene, from restaurants and bars to nonprofits and more.
Whether it was through our Reader's Choice Food Awards, where hundreds of votes pour in every year, or the Critic's Choice Food Awards, where the dining team selects the honorees, the local businesses we've highlighted over the years have impressed us and left their mark.
Below is a searchable list and a map of the winners of the Tribune Food Awards, excluding businesses that have closed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
GMS (NYSE:GMS) Surprises With Q1 Sales
Building materials distributor GMS (NYSE:GMS) reported Q1 CY2025 results topping the market's revenue expectations , but sales fell by 5.6% year on year to $1.33 billion. Its non-GAAP profit of $1.29 per share was 15.9% above analysts' consensus estimates. Is now the time to buy GMS? Find out in our full research report. Revenue: $1.33 billion vs analyst estimates of $1.30 billion (5.6% year-on-year decline, 2.9% beat) Adjusted EPS: $1.29 vs analyst estimates of $1.11 (15.9% beat) Adjusted EBITDA: $109.8 million vs analyst estimates of $104.5 million (8.2% margin, 5.1% beat) Operating Margin: 4.5%, down from 7.1% in the same quarter last year Free Cash Flow Margin: 13.7%, similar to the same quarter last year Organic Revenue fell 9.7% year on year (5.5% in the same quarter last year) Market Capitalization: $2.81 billion 'We reported solid results for our fourth quarter and full year fiscal 2025 despite deterioration in end market conditions as we moved through the year,' said John C. Turner, Jr, President and Chief Executive Officer of GMS. Founded in 1971, GMS (NYSE:GMS) distributes specialty building materials including wallboard, ceilings, and insulation products, to the construction industry. Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, GMS grew its sales at an impressive 11.2% compounded annual growth rate. Its growth beat the average industrials company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. GMS's recent performance shows its demand has slowed significantly as its annualized revenue growth of 1.7% over the last two years was well below its five-year trend. GMS also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, GMS's organic revenue averaged 2.4% year-on-year declines. Because this number is lower than its normal revenue growth, we can see that some mixture of acquisitions and foreign exchange rates boosted its headline results. This quarter, GMS's revenue fell by 5.6% year on year to $1.33 billion but beat Wall Street's estimates by 2.9%. Looking ahead, sell-side analysts expect revenue to decline by 1.2% over the next 12 months, a slight deceleration versus the last two years. This projection is underwhelming and implies its products and services will face some demand challenges. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. GMS was profitable over the last five years but held back by its large cost base. Its average operating margin of 7.5% was weak for an industrials business. Analyzing the trend in its profitability, GMS's operating margin decreased by 1.1 percentage points over the last five years. This raises questions about the company's expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. GMS's performance was poor no matter how you look at it - it shows that costs were rising and it couldn't pass them onto its customers. This quarter, GMS generated an operating margin profit margin of 4.5%, down 2.6 percentage points year on year. Since GMS's operating margin decreased more than its gross margin, we can assume it was less efficient because expenses such as marketing, R&D, and administrative overhead increased. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. GMS's EPS grew at a spectacular 15.7% compounded annual growth rate over the last five years, higher than its 11.2% annualized revenue growth. However, this alone doesn't tell us much about its business quality because its operating margin didn't improve. We can take a deeper look into GMS's earnings quality to better understand the drivers of its performance. A five-year view shows that GMS has repurchased its stock, shrinking its share count by 8.5%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings. Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business. For GMS, its two-year annual EPS declines of 18.1% mark a reversal from its (seemingly) healthy five-year trend. We hope GMS can return to earnings growth in the future. In Q1, GMS reported EPS at $1.29, down from $2.01 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects GMS's full-year EPS of $6.16 to stay about the same. We were impressed by how significantly GMS blew past analysts' organic revenue expectations this quarter. We were also glad its revenue outperformed Wall Street's estimates. Zooming out, we think this was a solid print. The stock remained flat at $73.50 immediately after reporting. Sure, GMS had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
30 minutes ago
- Yahoo
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)
Telemedicine company Hims & Hers Health has been one of the hottest healthcare stocks in recent memory. Changes at UnitedHealth Group have attracted the attention of investors, but a smaller player called Oscar Health is the one to pay attention to. Oscar Health's business model and approach are similar to Hims & Hers, and it seeks to disrupt legacy insurers. 10 stocks we like better than Oscar Health › When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services. With the exception of CVS, whose shares have risen 46% so far this year, none of the other companies have generated robust stock price returns so far in 2025. Lilly, Novo, and Johnson & Johnson are seeing share price pressure over concerns that President Donald Trump's administrative actions could impact the pharmaceutical industry -- particularly as it relates to tariffs and medication pricing. One healthcare player that is (so far) outmaneuvering investor trepidation throughout 2025 is telemedicine company (NYSE: HIMS). Its share price is up 138% in 2025 (as of June 17). While buying into Hims and Hers stock to follow the momentum is tempting, I think a different, dirt cheap health insurance stock is positioned for a breakout akin to Hims & Hers Health. And no, I'm not talking about the beaten-down UnitedHealth Group. Rather, I think Oscar Health (NYSE: OSCR) could be the next big multibagger in healthcare stocks. Curious? Read on to learn more about Oscar Health and why I'm so bullish on the stock. When it comes to accessing patient care, consumers have a couple of options. On one hand, they can take time to go to brick-and-mortar retailers like CVS to fulfill a prescription or take the time to schedule an appointment and wait in a busy doctor's office. Alternatively, they can streamline their efforts by using Hims & Hers telemedicine services to gain back some time (and possibly some money) while still accessing necessary health services and medications. This technology-first approach has served Hims well, particularly as it relates to acquiring customers across younger demographics such as Millennials and Gen-Z. This approach is by design as younger patients tend to be more receptive to the idea of accessing critical information (i.e., patient care) online as opposed to the traditional, time-consuming methods that include finding a doctor in your network, making an appointment, and waiting. Oscar is using a similar approach to transform access to health insurance. The company hopes to capture a strategic lead over competitors with a tech-first digital platform. While some legacy insurers have also invested in technology infrastructure, they did so by retrofitting archaic and antiquated manual processes into a technology platform that likely doesn't fit well with their original business models. Another important item to note is that Hims & Hers does not offer as comprehensive a service as going to a traditional doctor. In other words, Hims & Hers currently focuses on a handful of treatments across specific segments like mental health, sexual health, and weight management. Likewise, Oscar has a niche focus on Affordable Care Act (ACA) members and small employers that aren't covered by legacy health insurance providers. While Oscar's upside might appear limited given its niche focus, a look at its metrics suggests it still has some strong growth prospects. Despite an intense competitive landscape in the health insurance market, Oscar has identified pockets that it can dominate, as evidenced by the steepening slope of the revenue line over the last five years, coupled with rising cash flow and liquidity. The biggest risk surrounding Oscar right now has to do with potential changes in the regulatory landscape as it pertains to the ACA. While policy changes could put some pressure on Oscar's core business, the company is working to diversify its revenue stream by expanding into related markets -- just as Hims & Hers has done in recent years by getting into the weight management space, competing with the likes of Lilly and Novo. Data that Oscar Health recently provided to investors shows that its primary market of traditional ACA members totals roughly 21 million. However, by expanding into individual coverage health reimbursement arrangements (ICHRAs) with small and medium-sized businesses (SMB), Oscar could open up its total customer pool to 75 million -- growing its total addressable market (TAM) from $160 billion today to $720 billion. This expansion effort should help keep the company's growth prospects on track. Given that Oscar Health's modest market capitalization of just $4 billion is roughly in line with its cash balance, it would seem that Wall Street isn't placing much value on the company's insurance business. I suspect the market may be pricing in the potential for significant downside from changes to the ACA. It may also have some skepticism about the company's pursuit of ICHRAs with small businesses. This suggests another parallel between what Oscar is trying to achieve and what Hims was building during its early days. At the start, Hims faced some doubts over customer acquisition, subscriber retention, and its ability to truly compete with larger, legacy patient care providers. But look at Hims & Hers' share price gains now. Some of those gains are rooted in a turning-of-the-page bullish narrative from some pockets of the investment community. To be clear, there are potential near-term headwinds at Oscar, but I find the long-term vision is compelling. I'm cautiously optimistic that the company has what it takes to build, grow, and sustain a diversified healthcare platform -- just as Hims & Hers has done -- and that shares will see a sharp rise sooner than some may be anticipating. Before you buy stock in Oscar Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Oscar Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends CVS Health, Johnson & Johnson, Novo Nordisk, and UnitedHealth Group. The Motley Fool has a disclosure policy. Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Kneecap's Mo Chara bailed over terror offence charge
Liam Og O hAnnaidh, who performs under the stage name Mo Chara in the band Kneecap, has been released on unconditional bail after being accused of a terror offence. The 27-year-old appeared at Westminster Magistrates' Court on Wednesday, June 18, following an alleged incident during a gig at the O2 Forum in Kentish Town, north London. O hAnnaidh allegedly displayed a flag in a public place, 'in such a way or in such circumstances as to arouse reasonable suspicion that he is a supporter of a proscribed organisation' – namely, Hezbollah. His next hearing will be on August 20 when legal arguments will be dealt with. Inside the court, prosecutor Michael Bisgrove said: 'This case is not about Mr O hAnnaidh's support for the people of Palestine or his criticism of Israel.' He told the court O hAnnaidh is 'well within his rights' to express his support and solidarity for Palestinians. O hAnnaidh was first charged after the Metropolitan Police said it had been made aware of a video from the gig at the O2 Forum which had been posted online. In a separate event shortly after the terrorism charge, O hAnnaidh could be seen in social media videos entering the stage with tape covering his mouth. The Met previously said the Belfast rap trio were under investigation after clips posted online appeared to show the band calling for the deaths of MPs and shouting 'up Hamas, up Hezbollah'. Recommended Reading Kneecap 'plasters' London with message of support for group member due in court UK and Irish governments should 'consider their actions' over Kneecap funding Kneecap's surprise London performance begins a day after terror charge Kneecap said they have 'never supported' Hamas or Hezbollah, both of which are banned in the UK. Ahead of the singer's appearance in court, he described the prosecution as a 'witch hunt' in a post on X. The post included a short video which appeared to show a billboard that had been displayed in London. O hAnnaidh's next hearing will be on August 20 when legal argument will be dealt with.
